Karyopharm Therapeutics Inc. (NASDAQ: KPTI)
$0.98
-0.0206 ( -2.06% ) 653.3K
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Market Data
Open
$0.98
Previous close
$1.00
Volume
653.3K
Market cap
$121.58M
Day range
$0.96 - $1.04
52 week range
$0.62 - $1.95
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | May 30, 2024 |
4 | Insider transactions | 1 | May 30, 2024 |
4 | Insider transactions | 1 | May 30, 2024 |
8-k | 8K-related | 25 | May 14, 2024 |
10-q | Quarterly Reports | 62 | May 08, 2024 |
8-k | 8K-related | 15 | May 08, 2024 |
8-k | 8K-related | 15 | May 08, 2024 |
4 | Insider transactions | 1 | May 07, 2024 |
4 | Insider transactions | 1 | Apr 23, 2024 |
ars | Annual reports | 1 | Apr 19, 2024 |